Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.
Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation and dry eye disease. Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).
We have applied the MPP technology to create nanosuspensions of loteprednol etabonate, or LE, a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. We anticipate submitting new drug applications, or NDAs, for these product candidates by the end of 2017 and the first half of 2018, respectively.
The name Kala was inspired by the famous Kalalau trail, a hiking trail on the island of Kauai, Hawaii. This trail is not only notable for its strenuous path and terrain that is difficult to traverse but also known for its unsurpassed beauty.